Warner Pharmaceuticals announced that on July 31, 2026, the company participated in the 12th batch of centralized procurement bids for national drugs, and ferrous succinate tablets and diclofenac sodium sustained-release tablets will be selected. Sales revenue for ferrous succinate tablets in the first quarter of 2025 and 2026 was 894.55 million yuan and 19.622 million yuan, respectively; diclofenac extended-release tablets were 89.365 million yuan and 2019.63 million yuan respectively during the same period. The proposed selection price is lower than the original sales price. If a procurement contract is signed and executed later, it will help the product expand channels, expand the market, and increase brand influence. However, there is uncertainty about subsequent matters such as the signing of a procurement contract.

Warner Pharmaceuticals announced that on July 31, 2026, the company participated in the 12th batch of centralized procurement bids for national drugs, and ferrous succinate tablets and diclofenac sodium sustained-release tablets will be selected. Sales revenue for ferrous succinate tablets in the first quarter of 2025 and 2026 was 894.55 million yuan and 19.622 million yuan, respectively; diclofenac extended-release tablets were 89.365 million yuan and 2019.63 million yuan respectively during the same period. The proposed selection price is lower than the original sales price. If a procurement contract is signed and executed later, it will help the product expand channels, expand the market, and increase brand influence. However, there is uncertainty about subsequent matters such as the signing of a procurement contract.